Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 8/20 | 0.55 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1790919 | 0.89 | RPS6KB1 (0.57) | RPS6KB1MAPTTP53LMNATHRB | |
| SCHEMBL1790912 | 0.89 | RPS6KB1 (0.57) | RPS6KB1MAPTTP53LMNATHRB | |
| SCHEMBL4928994 | 0.89 | RPS6KB1 (0.52) | RPS6KB1MAPTTP53LMNATHRB | |
| Trifluoroacetic Acid SCHEMBL4928985 | 0.86 | RPS6KB1 (0.55) | RPS6KB1MAPTTP53LMNATHRB | |
| Trifluoroacetic Acid SCHEMBL4928998 | 0.86 | RPS6KB1 (0.55) | RPS6KB1MAPTTP53LMNATHRB | |
| SCHEMBL1793298 | 0.82 | RPS6KB1 (0.54) | RPS6KB1MAPTTP53LMNATHRB | |
| Trifluoroacetic Acid SCHEMBL4922202 | 0.79 | RPS6KB1 (0.53) | RPS6KB1MAPTTP53LMNATHRB | |
| SCHEMBL1793442 | 0.78 | RPS6KB1 (0.59) | RPS6KB1MAPTTP53LMNA | |
| SCHEMBL1793296 | 0.78 | RPS6KB1 (0.55) | RPS6KB1MAPTTP53LMNATHRB | |
| Trifluoroacetic Acid SCHEMBL4932722 | 0.78 | RPS6KB1 (0.51) | RPS6KB1MAPTTP53LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513266-B2 | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha | EXELIXIS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8481001-B2 | Combination therapies comprising quinoxaline inhibitors of P13K-alpha for use in the treatment of cancer | EXELIXIS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-7999006-B2 | Anticancer agents; mitogen-activated protein kinases (MEK) | EXELIXIS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC (US) | 2011-05-26 | — | — | US | disclosed |
| US-20100209420-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF P13K ALPHA | EXELIXIS, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100209420-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF P13K ALPHA | TP53, PHKG1, TNNI3K | RPS6KB1 444/4885MAPT 3399/4885TP53 1/4885 |
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | TP53, PHKG1, TNNI3K | RPS6KB1 329/4885MAPT 4242/4885TP53 1/4885 |
| US-20080166359-A1 | Methods of using MEK inhibitors | BRAF, NRAS, KRAS | RPS6KB1 700/4885MAPT 3423/4885TP53 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.